Brilliant Violet 421™ anti-mouse CD21/CD35 (CR2/CR1)

Antibodies Single
Sony
7E9
Flow Cytometry
Rat IgG2a, κ
Mouse
CD35/CFA
1217110
$283.00

Description

CD21, also known as CR2 (complement receptor 2) and C3d receptor, binds C3d and iC3b. It is also a receptor of Epstein-Barr virus. CD35, also known as CR1, binds C3b, iC3b, C4b, and iC4b. CD21/CD35 is primarily expressed on B lymphocytes, mast cells, follicular dendritic cells, macrophages, and activated granulocytes. CD21/CD35 forms part of the B-cell antigen receptor complex with CD19 and CD81 and is involved in signal transduction.

Formulation

microL size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
microg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.35 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Boackle S, et al. 2001 Immunity 15:775.